Key Metrics 
Check Before You Invest 
10 Yrs X-Ray 
Valuation 
Analyst Note 
Qtr. Results 
Financials 
News 
About
Piramal Pharma Ltd (PPLPHARMA)
Share Analysis – Quality, Valuation Zone, Price Trend & DeciZen Rating BSE: 543635 NSE: PPLPHARMA Pharmaceuticals & Drugs | Small Cap | Piramal Pharma Share Price
₹211.90 -0.60 (-0.28%)
As on 11-Sep'26 15:51
Piramal Pharma Ltd (PPLPHARMA)
Share Analysis – Quality, Valuation Zone, Price Trend & DeciZen Rating BSE: 543635 NSE: PPLPHARMA Pharmaceuticals & Drugs | Small Cap | Piramal Pharma Share Price
₹211.90 -0.60 (-0.28%)
As on 11-Sep'26 15:51
Key Metrics
Valuation Multiples
Market Cap
₹28,291 Cr.
Current Price
₹211.9
52-Week Low / High
₹133 / 232
TTM EPS
₹-2.4
TTM Sales
₹9,205 Cr.
Book Value per Share
₹60.1
P/E Ratio
0.00
Lower than its 5-year historical median
Industry PE
54.3
Price to Book (P/B)
3.53
Higher than its 5-year historical median
Price to Sales (P/S)
3.07
Lower than its 5-year historical median
EV/EBITDA
25.96
In line with its 5-year historical median
Dividend Yield
0%
Profitability Efficiency
Return on Equity (ROE)
-4.04%
Underperforms industry median
Return on Capital Employed (ROCE)
1.24%
Underperforms industry median
Return on Assets (ROA)
-1.98%
Operating Profit Margin
10.1%
Net Profit Margin
-3.68%
Gross Profit Margin
7.6%
Growth Momentum
1-yr vs 3-yr growth
1-yr vs 3-yr growth
Sales Growth (1 Year)
Slowing versus 3-year growth rate
-9.53%
Operating Profit Growth (1 Year)
Slowing versus 3-year growth rate
-37.05%
Net Profit Growth (1 Year)
-
-457.66%
Asset Quality
Promoter Holding
34.80%
Pledged shares (%) of Promoter's holding (%)
0.00%
Reserves
₹6,674 Cr.
Equity
₹1,331.4 Cr.
Face Value
₹10
All Time Low / High
₹61.65 / 307.85
Check Before You Invest
Quality
Not GoodValuation
OvervaluedCheck Valuation charts
Price Trend
Strong
Is Piramal Pharma Ltd a good quality company?
Piramal Pharma Ltd is a average quality company, based on a somewhat consistent multi-year financial track record.
This assessment is based on company’s performance on Revenue growth, ROCE, Equity and Assets, key margin ratios, cash conversion cycle, and debt to cash flow from operations and how it compares with its long term averages.
We have analysed the performance of the company on the following:
-
How has it performed on generating Profits?
By checking its Revenue growth, Gross, Operating and Net Margins compared to its last 5-year median.
-
How efficiently has it utilized Capital?
By checking its ROCE, ROA, ROE and its Cash Conversion Cycle.
-
How is it managing its Debt?
By checking its Debt to Equity and Cash Flow from Operations.
How does Piramal Pharma Ltd performance compare with that of its Peers?
Revenue growth of Piramal Pharma Ltd vs industry peers?
Piramal Pharma Ltd revenue CAGR is 10.23%, compared to the industry median CAGR of 5.76%, indicating faster growth and gaining its market share.
Promoter shareholding and pledge status of Piramal Pharma Ltd?
Promoters hold 34.80% of the Piramal Pharma Ltd, with 0.00% of their stake pledged, indicating no pledge risk.
Stock return of Piramal Pharma Ltd over the last decade?
Over the last 3 year(s), the stock has delivered a CAGR of 26.57% based on the current price.
10 Year X-Ray :
Analysis of Financial Track Record (Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end)
Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year endData adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end.
What is a Financial Track Record? How to read this chart in order to understand the data present here?
Financial track record gives insight into the company's performance on key parameters over the past ten years. MoneyWorks4me’s proprietary colour codes make it easy for retail investors to gauge the company’s past performance.
Piramal Pharma Ltd has not performed well majority of the past ten years indicating its past ten year financial track record is not good
Value Creation ⓘ
| Mar'21 | Mar'22 | Mar'23 | Mar'24 | Mar'25 | Mar'26 | TTM | |
|---|---|---|---|---|---|---|---|
| ROCE % ⓘ | 16.2% | 9.9% | 3.6% | 8.3% | 12.4% | 10.9% | - |
| Value Creation Index ⓘ | 0.4 | -0.1 | -0.7 | -0.4 | 0.1 | 0.0 | - |
Growth Parameters ⓘ |
|||||||
| Sales ⓘ | 2,939 | 3,340 | 3,443 | 4,390 | 5,286 | 4,782 | 4,937 |
| Sales YoY Gr. | - | 13.7% | 3.1% | 27.5% | 20.4% | -9.5% | - |
| Adj EPS ⓘ | 5.2 | 2.9 | -0.2 | 2.8 | 5.2 | 3.7 | 5.3 |
| YoY Gr. | - | -45.1% | -106.6% | NA | 87.4% | -28.8% | - |
| BVPS (₹) ⓘ | 40.3 | 42.2 | 43.1 | 50.5 | 55.8 | 60.8 | 61.5 |
| Adj Net Profit ⓘ | 533 | 349 | -23.7 | 367 | 690 | 492 | 700 |
| Cash Flow from Ops. ⓘ | 34.7 | 249 | 71.5 | 358 | 549 | 1,328 | - |
| Debt/CF from Ops. ⓘ | 4.8 | 4.6 | 22.8 | 3.2 | 2.2 | 0.5 | - |
CAGR ⓘ
| 9 Years | 5 Years | 3 Years | 1 Years | |||||
|---|---|---|---|---|---|---|---|---|
| Sales ⓘ | NA | 10.2% | 11.6% | -9.5% | ||||
| Adj EPS ⓘ | NA | -6.6% | NA | -28.8% | ||||
| BVPSⓘ | NA | 8.6% | 12.2% | 8.9% | ||||
| Share Price | - | - | 26.4% | 5.9% | ||||
Key Financial Parameters ⓘ
| Mar'21 | Mar'22 | Mar'23 | Mar'24 | Mar'25 | Mar'26 | TTM | |
|---|---|---|---|---|---|---|---|
| Return on Equity % ⓘ | 13 | 7.6 | -0.5 | 6.1 | 9.8 | 6.3 | 8.6 |
| Op. Profit Mgn % ⓘ | 21.1 | 14.3 | 2.8 | 13.7 | 19.1 | 13.1 | 14.5 |
| Net Profit Mgn % ⓘ | 18.1 | 10.5 | -0.7 | 8.4 | 13.1 | 10.3 | 14.2 |
| Debt to Equity ⓘ | 0 | 0.2 | 0.3 | 0.2 | 0.2 | 0.1 | - |
| Working Cap Days ⓘ | 0 | 287 | 329 | 327 | 310 | 342 | 141 |
| Cash Conv. Cycle ⓘ | 0 | 67 | 84 | 72 | 75 | 78 | 55 |
Valuation of Piramal Pharma - Consolidated
Analyst's Notes
No data found!
Management X-Ray
Shareholding Pattern
Promoter's Holding & Share Pledging
| Pledged * | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
* Pledged shares as % of Promoter's holding (%)
Financials
| PARTICULARS | Mar'21 | Mar'22 | Mar'23 | Mar'24 | Mar'25 | Mar'26 |
|---|---|---|---|---|---|---|
| Sales | 6,315 | 6,559 | 7,082 | 8,171 | 9,151 | 8,869 |
| Operating Expenses ⓘ + | 4,887 | 5,609 | 6,453 | 7,001 | 7,733 | 7,977 |
| Operating Profit ⓘ | 1,428 | 950 | 628 | 1,171 | 1,418 | 892 |
| Operating Profit Margin (%) | 22.6% | 14.5% | 8.9% | 14.3% | 15.5% | 10.1% |
| Other Income ⓘ + | 164 | 276 | 225 | 201 | 162 | 242 |
| Interest ⓘ | 163 | 198 | 344 | 448 | 422 | 341 |
| Depreciation ⓘ | 545 | 586 | 677 | 741 | 816 | 831 |
| Profit Before Tax ⓘ | 949 | 485 | -120 | 179 | 415 | -176 |
| Tax ⓘ | 114 | 109 | 66 | 161 | 324 | 150 |
| Profit After Tax | 835 | 376 | -186 | 18 | 91 | -326 |
| PAT Margin (%) | 13.2% | 5.7% | -2.6% | 0.2% | 1.0% | -3.7% |
| Adjusted EPS (₹) | 8.2 | 3.1 | -1.5 | 0.1 | 0.7 | -2.5 |
| Dividend Payout Ratio (%) | 0% | 0% | 0% | 81.70% | 20.40% | 0% |
| PARTICULARS | Mar'21 | Mar'22 | Mar'23 | Mar'24 | Mar'25 | Mar'26 | |||||
|---|---|---|---|---|---|---|---|---|---|---|---|
Equity and Liabilities | |||||||||||
| Shareholders Fund + | 5,605 | 6,697 | 6,774 | 7,884 | 8,063 | 8,090 | |||||
| Debt + | 2,700 | 3,281 | 4,686 | 3,655 | 4,209 | 5,048 | |||||
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | |||||
| Trade Payables | 918 | 1,026 | 1,193 | 1,538 | 1,534 | 2,479 | |||||
| Others Liabilities ⓘ | 1,534 | 1,713 | 1,785 | 1,848 | 1,562 | 1,950 | |||||
| Total Liabilities ⓘ | 10,756 | 12,717 | 14,437 | 14,925 | 15,369 | 17,567 | |||||
Fixed Assets | |||||||||||
| Net Fixed Assets ⓘ + | 6,105 | 6,879 | 7,469 | 7,990 | 8,133 | 8,691 | |||||
| CWIP ⓘ | 627 | 1,172 | 1,419 | 1,116 | 977 | 1,100 | |||||
| Investments ⓘ | 123 | 267 | 639 | 385 | 291 | 437 | |||||
| Inventories | 1,232 | 1,389 | 1,681 | 2,176 | 2,313 | 3,064 | |||||
| Trade Receivables | 1,575 | 1,785 | 1,799 | 2,134 | 2,350 | 2,158 | |||||
| Cash Equivalents | 406 | 329 | 308 | 483 | 501 | 1,224 | |||||
| Others Assets ⓘ | 689 | 895 | 1,122 | 642 | 804 | 893 | |||||
| Total Assets ⓘ | 10,756 | 12,717 | 14,437 | 14,925 | 15,369 | 17,567 | |||||
| PARTICULARS | Mar'21 | Mar'22 | Mar'23 | Mar'24 | Mar'25 | Mar'26 |
|---|---|---|---|---|---|---|
| Cash Flow From Operating Activity ⓘ + | 598 | 766 | 484 | 1,005 | 892 | 1,653 |
| Cash Flow From Investing Activity ⓘ + | -4,480 | -1,812 | -1,339 | -434 | -477 | -826 |
| Cash Flow From Financing Activity ⓘ + | 3,977 | 794 | 818 | -422 | -441 | -39 |
| Net Cash Flow ⓘ | 94 | -251 | -37 | 148 | -26 | 788 |
| PARTICULARS | Mar'21 | Mar'22 | Mar'23 | Mar'24 | Mar'25 | Mar'26 | ||||
|---|---|---|---|---|---|---|---|---|---|---|
| Ratios | ||||||||||
| ROE (%) | 14.9 | 6.11 | -2.77 | 0.24 | 1.14 | -4.04 | ||||
| ROCE (%) | 13.06 | 7.1 | 1.95 | 5.07 | 6.61 | 1.24 | ||||
| Asset Turnover Ratio | 0.65 | 0.62 | 0.6 | 0.64 | 0.7 | 0.64 | ||||
| PAT to CFO Conversion(x) | 0.72 | 2.04 | N/A | 55.83 | 9.8 | N/A | ||||
| Working Capital Days | ||||||||||
| Receivable Days | 82.10 | 83.90 | 80.70 | 76.20 | 77.10 | 78.20 | ||||
| Inventory Days | 64.20 | 65.50 | 69.10 | 74.70 | 77.10 | 93.30 | ||||
| Payable Days | 162.70 | 144.80 | 149.80 | 168.70 | 173.50 | 226.10 | ||||
Top 5 Mutual Funds Holding
Last Visited Stocks
Announcements
Piramal Pharma Ltd FAQs
The current trading price of Piramal Pharma on 11-Sep-2026 15:51 is ₹211.9.
Market capitalization or market cap is determined by multiplying the current market price of a company's shares with the total number of shares outstanding. As of 10-Sep-2026 the market cap of Piramal Pharma stood at ₹28,291.2 Cr
The latest P/E ratio of Piramal Pharma as of 10-Sep-2026 is 40.40.
The latest P/B ratio of Piramal Pharma as of 10-Sep-2026 is 3.46.
The 52-week high of Piramal Pharma is ₹231.8 and the 52-week low is ₹132.5.
The TTM revenue is Trailing Twelve Months sales. The TTM revenue/sales of Piramal Pharma is ₹4,937 ( Cr.) .
Past 10 year’s financial track record analysis by Moneyworks4me indicates that Piramal Pharma Ltd is a below average quality company.
The key valuation ratios of Piramal Pharma Ltd's currently when compared to its past seem to suggest it is in the Overvalued zone.
The Price Trend analysis by MoneyWorks4Me indicates it is Strong which suggest that the price of Piramal Pharma Ltd is likely to Rise in the short term. However, please check the rating on Quality and Valuation before investing
About Piramal Pharma Ltd
Piramal Pharma (PPL) is a leading pharmaceutical company with global operations, providing end-to-end pharma services to customers and a portfolio of differentiated pharma products across a domestic and global distribution network. It operates under three business verticals - Piramal Pharma Solutions, an integrated contract development and manufacturing organization (CDMO) having a product suite in niche areas such as highly potent Active pharmaceutical ingredients (APIs), Finished dosage forms (FDFs), antibody drug conjugates, potent sterile injectable, hormonal oral solid dosage forms, biologics and vaccines; Piramal Critical Care, a complex hospital generics (CHG) business in the areas of inhalation anaesthesia, injectable anaesthesia and pain management, intrathecal therapy and other injectable; and Piramal Consumer Healthcare (PCH) business, selling well-known OTC brands.
Business area of the company
The company is one of the India’s largest Pharmaceutical Company. PPL offers a portfolio of differentiated products and services through its global development and manufacturing facilities and a global distribution network in various countries. PPL includes Piramal Pharma Solutions (PPS), an integrated Contract Development and Manufacturing Organization; Piramal Critical Care (PCC), a Complex Hospital Generics business; and the India Consumer Healthcare business, selling over-the- counter products.
Businesses of the company
Piramal Pharma Solutions: Piramal Pharma Solutions (PPS) is a Contract Development and Manufacturing Organization (CDMO) offering end-to-end development and manufacturing solutions across the drug life cycle. PPS serves customers through a globally integrated network of facilities in North America, Europe, and Asia. This enables PPS to offer a comprehensive range of services, including drug discovery solutions, process and pharmaceutical development services, clinical trial supplies, commercial supply of APIs, and finished dosage forms.
Piramal Critical Care: Piramal Critical Care (PCC), a business division of Piramal Pharma, is one of the leaders in inhaled anesthetics and a global player in hospital generics. PCC is motivated by its vision of commitment to delivering critical care solutions for patients and healthcare providers across the globe, while achieving sustainable and profitable growth for all the stakeholders.
Piramal Consumer Healthcare: Piramal Consumer Healthcare (PCH) is one of the fastest-growing businesses of Piramal Pharma. It is among the leading players in the Indian self-care space, with established brands like Littles, Lacto Calamine, i-pill, Tetmosol. Polycrol and Tri-Activ, among others, in the Indian Consumer Healthcare market. The PCH portfolio consists of branded consumer healthcare and wellness products, primarily in areas of routine health disruption and proactive care, expanding across key over the counter (OTC) categories such as Analgesics, Gastro-Intestinal, Hygiene, Skincare, Vitamins and Supplements, Women Care, Baby Care and Kids’ wellness.
Awards and recognition
- 2019: Piramal Pharma honoured with 2019 Global Customer Service Leadership award by Frost & Sullivan.
- 2020: Piramal Pharma Solution received 'Manufacturing Supply Chain Operational Excellence – Pharmaceuticals' award at 7th and 9th Edition of Manufacturing Supply Chain Awards.
- 2020: Piramal Pharma Solutions was recognised as the 'Best Contract Manufacturing (CMO) Provider' at the 7th Annual World ADC Awards.
- 2021: Piramal Pharma Solutions was awarded the ‘2021 Global Contract Development and Manufacturing Organisation Customer Value Leadership Award’ by Frost & Sullivan at the 2021 MEASA Best Practices Awards.
- 2022: Piramal Pharma Ltd-Consumer Products Division was certified by Great Place to Work® Institute, India.
- 2022: Piramal Pharma Ltd - Consumer Products Division was awarded Best Sales Automation (in CPG) by Bizom.
- 2023: Piramal Pharma Solutions retains No. 1 position in Indian Bioservices Industry.
- 2024: Piramal Pharma Solutions Receives the 2024 CDMO Leadership Award.
- 2025: Piramal Pharma Solutions Wins Outsourced Pharma's CDMO Leadership 2025 Award.
Milestones
- 1988: Acquired Nicholas Laboratories, marking entry into pharmaceuticals.
- 1991: Commissioned first formulation plant in Pithampur, Madhya Pradesh, expanding operations in 1992.
- 1992: Renamed Nicholas Laboratories Ltd. to Nicholas Piramal India Ltd.
- 1993: Entered into a joint venture with Allergan, a leader in ophthalmic products.
- 1993: Acquired Roche India’s domestic formulations and nutrition products/ services business.
- 1994: Acquired Boehringer Mannheim's formulation plant in Mahad.
- 1995: Acquired the bulk drug division of Sumitra Pharmaceutical and Chemical Ltd., Hyderabad.
- 1996: Boehringer Mannheim fully acquired.
- 2000: Began collaborative research in gene technology with the Centre for Biochemical Technology.
- 2002: Acquired ICI Pharma.
- 2003: Acquired Global Bulk Drugs.
- 2005: Acquired Avecia Pharmaceuticals.
- 2006: Acquired Morpeth facility from Pfizer.
- 2009: Greenfield investment in Ahmedabad (PPDS).
- 2011: Acquired Oxygen Bio Research, a CRO based in Ahmedabad.
- 2012: Piramal Healthcare renamed to Piramal Enterprises, integrating pharma, Financial Services (FS), and new businesses created / acquired – FS and DRG.
- 2015: Acquired Kentucky-based CDMO Coldstream Laboratories Inc.
- 2016: Acquired Ash Stevens Inc., a U.S.-based developer specializing in high-potency APIs.
- 2020: Acquired solid oral dosage drug product facility in Sellersville, Pennsylvania, from G&W Laboratories Inc.
- 2020: Becomes a subsidiary of Piramal Enterprises and receives strategic growth investment by Carlyle.
- 2021: Acquired Hemmo Pharmaceuticals, a leading Indian manufacturer of peptide APIs.
- 2021 Acquired a minority stake in Yapan Bio, an Indian CDMO specializing in biologics and vaccines.
- 2022: NCLT approves Piramal Enterprises demerger and Piramal Pharma Limited lists on BSE and NSE.
- 2022: Opens a new state-of-the-art API manufacturing facility in Aurora, Canada.
- 2023: Opens a new state-of-the-art API manufacturing facility in Riverview, Michigan.
- 2023: Opens its expanded antibody-drug conjugate (ADC) manufacturing facility in Grangemouth, Scotland, UK.
- 2024: PPL forays into men’s grooming market in India with the launch of BOHEM.
- 2024: Piramal Pharma’s GHG Commitment Validated and Approved by SBTi.
- 2024: Capacity Expansion at Piramal Pharma Solutions’ Facility at Lexington, Kentucky.
- 2024: Piramal Pharma ropes in Mrunal Thakur as its brand ambassador for Lacto Calamine.
- 2025: Piramal Pharma Limited Converts the Coal-Fired Steamer at its Digwal Facility to Operate on Biomass Briquettes, Advancing Decarbonization Efforts.
- 2025: Piramal Critical Care Announces U.S. Launch of Chlorpromazine Hydrochloride for Injection, USP.
- 2025: Piramal Pharma ropes in Yami Gautam as its brand ambassador for Brand,Little’s.
- 2025: Piramal Pharma Solutions Augments Formulation Capabilities with the Addition of New Korsch XM-12 Bilayer Tablet Press at its Morpeth, UK Facility.
- 2025: Piramal Pharma Solutions Achieves Regulatory Compliance for Nitrosamine Impurities.
- 2026: Piramal Pharma Limited’s Consumer Healthcare launches Little’s AquaSense Baby Wipes - 99.9% Water.
- 2026: Piramal Pharma Solutions Introduces Tablet-in-Capsule Capabilities.
- 2026: Piramal Consumer Healthcare’s Tetmosol Announces Pankaj Tripathi as Brand Ambassador; Launches New Campaign and Expands Portfolio.
You have 46 views remaining as a Guest User. To get DeciZen Rating of 3,500+ Stocks based on their Quality, Valuation and Price Trend Login Now
